Rubén Andújar-Espinosa

Prof. Dr. Rubén Andújar-Espinosa

University of Murcia
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
JSJoaquin Sastre
Joaquin Sastre
ACAstrid Crespo
Astrid Crespo
AFAntonio Fernandez-Sanchez
Antonio Fernandez-Sanchez
MRManuel Jorge Rial
Manuel Jorge Rial
VPVicente Plaza
Vicente Plaza
NAN. Segura Arazuri
N. Segura Arazuri

5 November 2020 in Thorax
Verified
Journal Article
Closed access
PDF file
RARubén Andújar-Espinosa
Rubén Andújar-Espinosa
LSLourdes Salinero-González
Lourdes Salinero-González
FIFátima Illán-Gómez
Fátima Illán-Gómez
MCManuel Castilla-Martínez
Manuel Castilla-Martínez
CHChunshao Hu-Yang
Chunshao Hu-Yang
FRFrancisco José Ruiz-López
Francisco José Ruiz-López
Background: The relationship between asthma and vitamin D deficiency has been known for some time. However, interventional studies conducted in this regard have shown conflicting results.Objective: To evaluate the efficacy of vitamin D supplementation in asthmatic patients in improving the degree of control of asthma.Methods: Randomised, triple-blind, placebo-controlled, parallel-group study in adult asthmatic patients with serum 25-hydroxyvitamin-D3 <30 ng/mL. The intervention group received oral supplementation with 16 000 IU of calcifediol per week, and the control group had placebo added to their usual asthma treatment. The study period was 6 months. The primary endpoint was the degree of asthma control as determined by the asthma control test (ACT). Secondary endpoints included quality of life measured using the mini Asthma Quality of Life Questionnaire, the number of asthma attacks, oral corticosteroid cycles, the dose of inhaled corticosteroids, number of emergency visits, unscheduled consultations with the primary care physician and hospitalisations for asthma.Results: One hundred and twelve patients were randomised (mean age 55 years, with 87 (78%) being women). Of the 112 patients, 106 (95%) completed the trial. Half the patients (56) were assigned to the intervention group and the other half to the control group. A statistically significant clinical improvement was observed in the intervention group (+3.09) compared with the control group (−0.57) (difference 3.66 (95% CI 0.89 to 5.43); p<0.001) as measured using ACT scores. Among the secondary endpoints, a significant improvement in the quality of life was found in the intervention group (5.34), compared with the control group (4.64) (difference 0.7 (95% CI 0.15 to 1.25); p=0.01).Conclusion: Among adults with asthma and vitamin D deficiency, supplementation with weekly oral calcifediol compared with placebo improved asthma control over 6 months. Further research is needed to assess long-term efficacy and safety.Trial registration number: NCT02805907.

1 May 2019 in Respiratory Medicine
Verified
Journal Article
Closed access
LLLuis Pérez de Llano
Luis Pérez de Llano
EMEva Martinez-Moragon
Eva Martinez-Moragon
VPVicente Plaza
Vicente Plaza
AAAndrea Trisan Alonso
Andrea Trisan Alonso
CSCarlos Almonacid Sánchez
Carlos Almonacid Sánchez
Borja G CosíoBorja G Cosío
Borja G Cosío

1 August 2016 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
RBRoberto Bernabeu-Mora
Roberto Bernabeu-Mora
JSJuan Miguel Sánchez-Nieto
Juan Miguel Sánchez-Nieto
RARubén Andújar-Espinosa
Rubén Andújar-Espinosa
CHChunshao Hu
Chunshao Hu
BGBeatriz Gálvez-Martínez
Beatriz Gálvez-Martínez
EAEva Abad-Corpa
Eva Abad-Corpa
Background: Self-management interventions improve different outcome variables in various chronic diseases. Their role in COPD has not been clearly established. We assessed the efficacy of an intervention called the self-management program on the need for hospital care due to disease exacerbation in patients with advanced COPD. Methods: Multicenter, randomized study in two hospitals with follow-up of 1 year. All the patients had severe or very severe COPD, and had gone to either an accident and emergency (A&E) department or had been admitted to a hospital at least once in the previous year due to exacerbation of COPD. The intervention consisted of a group education session on the main characteristics of the disease, an individual training session on inhalation techniques, at the start and during the 3rd month, and a written action plan containing instructions for physical activity and treatment for stable phases and exacerbations. We determined the combined number of COPD-related hospitalizations and emergency visits per patient per year. Secondary endpoints were number of patients with visits to A&E and the number of patients hospitalized because of exacerbations, use of antibiotics and corticosteroids, length of hospital stay, and all-cause mortality. Results: After 1 year, the rate of COPD exacerbations with visits to A&E or hospitalization had decreased from 1.37 to 0.89 (P=0.04) and the number of exacerbations dropped from 52 to 42 in the group of patients who received the intervention. The numbers of patients hospitalized, at 19 (40.4%) versus 20 (52.6%) (P=0.26), and those who went to A&E, at 9 (19.1%) versus 14 (36.8%) (P=0.06), due to exacerbation of COPD were also lower in this group. Intake of antibiotics was higher in the intervention group, whereas use of glucocorticoids was slightly lower, though there were no significant differences (P=0.30). There were also no differences between groups in the length of hospital stay (P=0.154) or overall mortality (P=0.191). Conclusion: The implementation of a self-management program for patients with advanced COPD reduced exacerbations that required hospital care.

28 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMyriam Calle Rubio
Myriam Calle Rubio
JSJoan B Soriano
Joan B Soriano
Jose Luis Lopez-CamposJose Luis Lopez-Campos
Jose Luis Lopez-Campos
JSJuan J. Soler-Cataluña
Juan J. Soler-Cataluña
BABernardino Alcazar
Bernardino Alcazar
RARubén Andújar-Espinosa
Rubén Andújar-Espinosa
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults, but is under-recognized. In Spain, the number of patients diagnosed with AATD is much lower than expected according to epidemiologic studies. The objectives of this study were to assess the frequency and determinants of testing serum α1-antitrypsin (AAT) levels in COPD patients, and to describe factors associated with testing. EPOCONSUL is a cross-sectional clinical audit, recruiting consecutive COPD cases over one year. The study evaluated serum AAT level determination in COPD patients and associations between individual, disease-related, and hospital characteristics. A total of 4,405 clinical records for COPD patients from 57 Spanish hospitals were evaluated. Only 995 (22.5%) patients had serum AAT tested on some occasion. A number of patient characteristics (being male [OR 0.5, p < 0.001], ≤55 years old [OR 2.38, p<0.001], BMI≤21 kg/m2 [OR 1.71, p<0.001], FEV1(%)<50% [OR 1.35, p<0.001], chronic bronchitis [OR 0.79, p < 0.001], Charlson index ≥ 3 [OR 0.66, p < 0.001], or history or symptoms of asthma [OR 1.32, p<0.001]), and management at a specialized COPD outpatient clinic [OR 2.73,p<0.001] were identified as factors independently associated with ever testing COPD patients for AATD. Overall, 114 COPD patients (11.5% of those tested) had AATD. Of them, 26 (22.8%) patients had severe deficiency. Patients with AATD were younger, with a low pack-year index, and were more likely to have emphysema (p<0.05). Testing of AAT blood levels in COPD patients treated at outpatient respiratory clinics in Spain is infrequent. However, when tested, AATD (based on the serum AAT levels ≤100 mg/dL) is detected in one in five COPD patients. Efforts to optimize AATD case detection in COPD are needed.

1 November 2022 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
JMJuan Carlos Miralles-López
Juan Carlos Miralles-López
RARubén Andújar-Espinosa
Rubén Andújar-Espinosa
FBFrancisco Javier Bravo-Gutiérrez
Francisco Javier Bravo-Gutiérrez
MCManuel Castilla-Martínez
Manuel Castilla-Martínez
IFIsabel Flores-Martín
Isabel Flores-Martín
RGRE-ASGRAMUR GROUP
RE-ASGRAMUR GROUP
Introduction: Clinical trials and real-life studies have been published showing effectiveness of benralizumab in severe eosinophilic asthmatic patients. The aim of the present study is to describe super-responders to benralizumab in a series of 79 patients who completed at least 1 year of treatment, and to compare super-responders with non super-responders. Methods: This is a multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed in eight hospitals under the conditions of routine clinical practice. Patients with zero exacerbations and no oral corticosteroid therapy for asthma were considered super-responders. We analyzed clinical, functional, and inflammatory parameters of selected patients.Results: In all, 50 of the 79 patients (63%) met the super-responder criteria. In addition, 36% of the patients (26/71) were considered as complete responders to treatment (superresponder + Asthma Control Test [ACT] ≥ 20 + forced expiratory volume in 1 s [FEV1] ≥ 80%). The super-responders were significantly older in age (P = 0.0029), had higher eosinophils count (P = 0.0423), higher proportion of nasal polyps (P = 0.036), and they had less severe disease at baseline. After 1 year of treatment, the super-responders had higher levels of ACT questionnaire (23 vs 19, P = 0.0007) and better percentage of FEV1 (83 vs 75, P = 0.0359). Conclusion: Almost two of the three patients treated with benralizumab were super-responders after 1 year of treatment and 36% had a complete response. Super-responders were associated with older age, higher eosinophils count, had nasal polyposis as comorbidity, and had less severe disease at baseline. This data illustrated the good real-life response of patients with severe eosinophilic asthma to the treatment with benralizumab.